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Men with prostate cancer die predominantly from metastatic disease that is resistant to androgen deprivation therapy. Although the complete cause of castration resistance is not known, recent studies indicate that a large percentage of castration-resistant tumors progress by maintaining androgen receptor-dependent signaling. Mechanisms underlying the preservation of androgen receptor signaling include androgen receptor overexpression, growth factor-regulated androgen receptor activation and de novo intracrine androgen production [1] [2] [3] [4] . New treatments designed to block androgen receptor activity (MDV3100) and steroidal synthesis (for example, abiraterone or TAK-700) have entered the clinic with promising preliminary results.
Despite these advances, it is not certain that androgen receptor reactivation is the only cause of castration resistance or that abrogation of androgen receptor signaling will result in cure. Lethal prostate cancers are heterogeneous, with pockets of cells that overexpress androgen receptor and others that do not express detectable androgen receptor 5, 6 . Initial results with the newest androgen receptor-targeted drugs are extremely promising, but early data suggest that 30% of patients do not respond at all, and 30-40% have only partial responses 7, 8 . The mechanisms by which tumors resist newer antiandrogens are not known, but the existence of tumors that are resistant to these approaches suggests that some tumors may be androgen receptor independent or only partially androgen receptor dependent.
There are a number of potential androgen receptor-independent mechanisms of castration resistance. For example, castration induces multiple antiapoptotic genes 9, 10 . Recent clinical studies of agents that block these pathways have had initial promise. There has also been a surge of interest in the role of prostate cancer stem cells in prostate cancer development and progression 11, 12 . Although controversial, some studies suggest that normal and prostate cancer stem cells may not express androgen receptor, implying that prostate cancers may become castration resistant through survival and expansion of cancerinitiating cells that lack functional androgen receptor.
To identify alternative pathways of castration resistance, we compared gene expression in matched androgen-dependent and CRPC xenografts. N-cadherin, a mesenchymal cadherin associated with epithelial-to-mesenchymal transition (EMT), was reproducibly upregulated in several models of castration-resistant cancer. We validated the association of N-cadherin with castration resistance in clinical samples of CRPC. These findings prompted us to perform a series of in vitro and in vivo studies, with the hypothesis that N-cadherin is crucial in prostate cancer progression not only to metastasis, but also to castration resistance. Because N-cadherin is expressed on the cell surface, we also asked whether therapeutic targeting with N-cadherin-specific monoclonal antibodies would have efficacy in preclinical models. The major findings of our study are that N-cadherin expression is sufficient to cause invasive, metastatic and castrationresistant prostate cancer and that these effects can be inhibited by N-cadherin-specific antibodies. Furthermore, N-cadherin-specific antibodies can inhibit the growth of both androgen receptor-positive and androgen receptor-negative prostate cancers. These studies identify a previously unknown pathway responsible for metastasis and castration resistance and validate N-cadherin as a promising new target for prostate cancer treatment.
RESULTS

N-cadherin is upregulated in CRPC
To identify markers of castration resistance, we compared gene expression in paired hormone-sensitive (AD) and castration-resistant (CR) LAPC9 xenografts 13 . N-cadherin expression was highly elevated in LAPC9-CR xenografts 13 , which we confirmed by further screening of independently derived LAPC4 and LAPC9 xenografts (Fig. 1a) . N-cadherin was absent in hormone-sensitive LNCaP but present in castration-resistant 22RV1, PC3 and LNCaP-CL1 14 prostate cancer cell lines (Fig. 1b) . These data suggest that expression of N-cadherin is a common event in CRPC progression.
Next, we evaluated the kinetics of N-cadherin expression in serial passages of LAPC9-CR tumors in castrated mice. We detected N-cadherin in 1-5% of cells in tumors after the first passage, but it was present in 50% of cells by passage 5 (Fig. 1c) , concomitant with gradual loss of E-cadherin and androgen receptor expression (Fig. 1d) . These results suggest that N-cadherin-positive cells may have a growth advantage over N-cadherin-negative cells in castrated mice and that N-cadherin may be involved in the modulation of E-cadherin and androgen receptor expression.
To determine whether N-cadherin is expressed in clinical CRPC, we performed quantitative PCR and immunohistochemistry on 21 soft-tissue and bone metastases obtained from men who died from prostate cancer. N-cadherin was expressed in 16 of 21 metastases (Fig. 1e) . Immunohistochemical staining confirmed N-cadherin protein expression in cases with high N-cadherin mRNA levels ( Fig. 1f) and in three of six additional CRPC bone metastases. We also stained three tissue microarrays containing samples from individuals with benign prostatic hyperplasia, hormone-naive prostate cancer, prostate cancer treated with 3-9 months of neoadjuvant hormone ablation, and CRPC. We detected N-cadherin expression in 16.7%, 28%, 34% and 67% of these samples, respectively. The mean percentage of cells staining positive for N-cadherin among all samples increased from 1% in benign prostatic hyperplasia to 9.5% in hormone-naive disease, 22.5% in men treated with neoadjuvant androgen deprivation and 41% in CRPC (P < 0.01) ( Supplementary  Fig. 1 ). These data demonstrate that N-cadherin expression is rare in untreated androgen-dependent prostate cancer, increases with androgen deprivation and is highest in CRPC.
N-cadherin causes invasion, metastasis and castration resistance
To evaluate the role of N-cadherin in prostate cancer, we ectopically expressed N-cadherin in multiple AD cell lines (LNCaP, MDAPCa-2b and LAPC4). N-cadherin-positive cells appeared flattened and fibroblastic, concomitant with loss of E-cadherin and gain of vimentin, although one low-expressing LNCaP subline (C3) retained E-cadherin and did not change morphologically (Fig. 2a,b) . All N-cadherin-expressing cell lines (including C3) became more invasive (Fig. 2c) , and invasiveness correlated with N-cadherin abundance, indicative of a gene dosage effect. When implanted subcutaneously, N-cadherin-positive tumors invaded underlying muscle and spread to distant lymph nodes (Fig. 2a,c) . Conversely, silencing N-cadherin in castration-resistant PC3 and CL1 cells reduced invasiveness (Fig. 2d) . These data suggest that N-cadherin expression is sufficient to cause EMT, invasion and metastasis in prostate cancer cells.
The association of N-cadherin with CRPC suggested that it might have a role in castration resistance. Consistent with this hypothesis, N-cadherin-expressing cell lines (MDA-N and LNCaP-C1, LNCa-C2 and LNCa-C3) could proliferate in the absence of androgen in vitro (Fig. 2e) . Most importantly, N-cadherin expression conferred castration resistance in vivo, as evidenced by the ability of all N-cadherin-transduced cell lines to form tumors in castrated mice (Fig. 2f) . Castration-resistant growth correlated with the level of N-cadherin expression, with LNCaP-C1 cells growing more rapidly than C2 and C3 cells in vitro and in vivo (Fig. 2e,f) . To determine whether N-cadherin is required for castration resistance, we knocked it down in PC3 and LNCaP-CL1 cells. Stable silencing of N-cadherin significantly (P = 0.005) impaired the ability of both cell lines to form tumors in castrated mice (Supplementary Fig. 2 ). These data suggest that N-cadherin expression is both sufficient and necessary for castration resistant growth. N-cadherin expression led to an inverse loss of androgen receptor, with high expressors (LNCaP-C1, PC3 and CL1) losing androgen receptor completely and low-expressors (LNCaP-C3) retaining it ( Fig. 1a and Fig. 2b) . We saw a similar pattern in LAPC9-CR cells, with some cells expressing androgen receptor, some expressing N-cadherin and others expressing both androgen receptor and N-cadherin ( Supplementary Fig. 3 ). These data indicate that N-cadherin is sufficient to cause androgen receptor-independent prostate cancer. However, many prostate cancers coexpress N-cadherin and androgen receptor, suggesting that these factors may act synergistically to promote castration-resistant growth. 
N-cadherin antibodies inhibit growth of CRPC
The presence of N-cadherin in metastatic prostate cancer and its ability to promote castration resistance suggested that N-cadherin might be a therapeutic target in advanced prostate cancer. We generated a panel of monoclonal antibodies specific for the extracellular domain of N-cadherin to test this hypothesis and to determine which domains are necessary for its effects in prostate cancer. We screened antibodies for cell surface recognition of N-cadherin and an ability to inhibit invasion in vitro. We selected two antibodies: 1H7, a mouse IgG1, recognizes an epitope within the first three extracellular domains, whereas 2A9, an IgG2a, recognizes an epitope in the fourth domain. Both antibodies inhibited invasion, attachment and proliferation of PC3 and LNCaP-C1 cells in vitro (Fig. 3a,b) . Upon exposure to either antibody, PC3 and LNCaP-C1 cells showed morphologic changes, such as increased polarity, resembling an epithelial phenotype (data not shown). These results suggest that N-cadherin-specific antibodies can affect multiple parameters of in vitro growth, including invasion, proliferation, attachment and potentially EMT.
We next asked whether N-cadherin-specific antibodies could affect invasion, metastasis and castration-resistant tumor growth in vivo. Castrated mice bearing palpable PC3, LAPC9-CR and LNCaP-C1 tumors were treated twice weekly with PBS or the antibodies 1H7 or 2A9 (10 mg per kg body weight) for 2 weeks. Both antibodies inhibited tumor growth (Fig. 3c) . The antibody-treated tumors were pale, nonadherent to underlying muscle, and noninvasive histologically, whereas control tumors grossly invaded underlying muscle (Fig. 3d) . In addition, N-cadherin-specific antibody-treated mice had rare distant lymph node metastases (one out of five mice treated with 1H7, zero of five mice treated with 2A9), whereas 100% of nodes (five of five) were replaced by cancer in control mice (Fig. 3d) . Prolonged administration of 2A9 led to long-term growth suppression and a >100% mean improvement in survival of mice bearing PC3 tumors (Fig. 3e) . Treated tumors had large areas of cell loss, reduced proliferation (Ki-67 staining), fewer blood vessels (CD31 staining), less vimentin staining and lower N-cadherin expression compared to untreated tumors (Fig. 4 and Supplementary Fig. 4 ).These data indicate that antibodies targeting the N-cadherin ectodomain are able to inhibit tumor growth, local invasion and metastasis of CRPC.
We also administered N-cadherin-specific antibodies to mice with larger established tumors. Both antibodies significantly slowed the growth of all three tumor models, although 2A9 suppressed growth better than 1H7 in most experiments (Fig. 5a) . Dose escalation of 2A9 to 20 mg per kg body weight led to complete regression of >50% of PC3 tumors, whereas no additional benefit was seen with 40 mg per kg body weight (Fig. 5b) . To examine the mechanism of tumor regression, we collected a subset of tumors within days of starting antibody treatment (Fig. 5c) . We saw large areas of cell loss and necrosis in treated tumors, as well as more caspase-3 staining (Fig. 5d) , suggesting that apoptosis may temporally precede the cell loss seen after prolonged treatment. These data show that N-cadherin-specific antibodies can suppress the growth of large established tumors and that higher doses can cause tumor regression. growth (Fig. 5e,f) . Of note, only ~4% of cells in the untreated control tumors expressed N-cadherin, consistent with previous experiments showing that N-cadherin is expressed by a minority of cells in earlypassage CR tumors (Fig. 1c) . These data suggest that N-cadherin is required for the development of castration resistance and that therapeutic targeting of N-cadherin in AD tumors (even in a minority of cells) can markedly delay the emergence of CRPC.
N-cadherin alters expression of genes implicated in CRPC
To gain insight into the mechanism of N-cadherin activity in prostate cancer, we compared the expression profiles of N-cadherin-transduced cells and controls. We selected genes previously shown to be associated with progression of LNCaP cells to the castration-resistant LNCaP-CL1 subline as a starting point 14 .
As predicted, N-cadherin-transduced cells showed the characteristic changes of an EMT, with decreased E-cadherin expression (Fig. 6a) and increased vimentin expression (data not shown). These changes were proportional to the level of N-cadherin expression. Other notable changes included increased B cell lymphoma-2 (bcl-2) expression (data not shown), increased transforming growth factor-β1 (TGF-β1), TGF-β2 and vascular endothelial growth factor (VEGF) expression, reduced androgen receptor and prostate-specific antigen expression and increased IL-6 and IL-8 expression (Fig. 6a) . The loss of androgen receptor is consistent with our observation in LAPC-9 cells that N-cadherin expression is inversely correlated with androgen receptor expression. Bcl-2 expression may explain the ability of N-cadherin-positive cells to survive in an androgendepleted environment 15 . TGF-β can induce EMT and might mediate N-cadherin signal transduction. TGF-β, IL-6 and IL-8 have all previously been implicated in CRPC 16, 17 . Silencing of N-cadherin in PC3 cells decreased IL-6, IL-8, vimentin, TGF-β and VEGF expression but did not restore androgen receptor or E-cadherin expression, suggesting that more prolonged knockdown might be required for complete reversal of EMT (Supplementary Fig. 5 ). Previous studies have associated N-cadherin with phosphoinositide 3-kinase-AKT pathway activation 15 . N-cadherin silencing reduced AKT phosphorylation, whereas N-cadherin overexpression correlated with increased AKT activity (Fig. 6b,c) . These results indicate that N-cadherin is sufficient to cause EMT and regulates the expression of multiple genes implicated in castration resistance.
N-cadherinantibody reduces AKT activity and IL-8 secretion
To determine the effects of N-cadherin-targeting antibody treatment on gene expression, we exposed PC3 and LNCaP-C2 cells in vitro to 2A9 and determined whether 2A9 reduced AKT kinase activity and IL-8 production. 2A9 reduced both phospho-AKT abundance and AKT kinase activity over a 4-to 24-h time period (Fig. 6d) . ELISA of cell culture media after 2A9 treatment showed a >50% reduction in IL-8 secretion (Fig. 6e) . 2A9 treatment also led to progressive declines in serum IL-8 that correlated with antibody dose and tumor regression (Fig. 6f) . These data indicate that the N-cadherin-specific antibody 2A9 can reverse N-cadherin-induced activation of AKT and IL-8 expression and may explain, at least in part, the antitumor activity of this antibody. IL-8 could serve as a potential biomarker of N-cadherin and N-cadherin-targeted therapy.
DISCUSSION N-cadherin expression is reproducibly associated with progression to castration resistance in both LAPC4 and LAPC9 prostate cancer xenografts. N-cadherin is expressed in multiple CRPC cell lines and in a majority of metastatic and castration-resistant prostate cancer tissues. N-cadherin induction after neoadjuvant hormone ablation supports the association of this protein with castration resistance. Our findings differ somewhat from previous studies that have reported higher N-cadherin expression in high-risk primary tumors. For example, one group reported that N-cadherin was expressed in 50% of high-grade primary tumors and lymph node metastases 18 and in 65% of tumors with Gleason score of ≥ 7 (ref. 19 ). Another study showed that an E-to N-cadherin switch in primary tumors was predictive of recurrence and prostate cancer-related death 20 . Some of the differences between our results and those of these studies might be ascribed to technical issues such as antibody selection. Differences in the subject populations (that is, Europe versus US) might also explain the differences in reported expression between the studies. Regardless, our study and others confirm that N-cadherin is expressed in a considerable percentage of human prostate cancers and validate N-cadherin as a promising therapeutic target in this disease. N-cadherin expression increases with passaging of castration-resistant tumors in our xenograft models, suggesting that N-cadherin-positive cells have a growth advantage over N-cadherin-negative cells and that a small percentage of N-cadherin-positive cells may be sufficient to drive castration resistance. Consistent with these hypotheses, N-cadherinpositive cells proliferate more rapidly than N-cadherin-negative cells. N-cadherin-positive cells from LAPC9-CR tumors are also more tumorigenic than N-cadherin-negative cells (E.K. and R.E.R., unpublished data). A number of recent studies have linked EMT and EMT-associated genes with cancer stem cells. Induction of EMT in immortalized mammary cells produced cells with stem cell properties such as mammosphere formation and tumorigenicity 21 . These studies raise the possibility that N-cadherin may be a marker for a population of castration-resistant stem cells in prostate cancer. This possibility is supported by our finding that N-cadherin-positive cells are tumorigenic and that antibody treatment was sufficient to delay progression to castration resistance, even though N-cadherin was only expressed by a small percentage of cells in the untreated controls. It is also supported by our finding that N-cadherin is expressed by only a fraction of cells in many human primary tumors, and this expression increases after androgen ablation and recurrence. Additionally, many stem cell-associated genes are upregulated in N-cadherin-positive cells (Supplementary Fig. 6 ) 22 . Additional studies will be required to establish whether N-cadherin-expressing cells are prostate cancer stem cells and whether they are required for castration-resistant or metastatic progression. Nevertheless, our data suggest that targeting of a small subset of cells with the potential to initiate castration-resistant tumor growth may be sufficient to have a therapeutic impact on this disease. N-cadherin expression was associated with a loss or reduction in androgen receptor expression. N-cadherin-positive tumors expressed lower levels of androgen receptor than androgen-dependent control tumors, and double-staining of LAPC9-CR tumors confirmed that androgen receptor was absent in a subset of N-cadherin-positive tumor cells. Forced N-cadherin expression resulted in androgen receptor loss proportional to the level of N-cadherin expression in LNCaP sublines. The mechanism by which N-cadherin reduces androgen receptor expression is not known. Additional studies will be required both to confirm this inverse correlation and to elucidate the pathway by which N-cadherin regulates androgen receptor. However, the major implication of our data is that N-cadherin may be a cause of androgen receptor-independent prostate cancer or may synergize with low-level androgen receptor expression. It will be crucial to determine whether N-cadherin can cause resistance to newer androgen receptor-targeted therapies.
The major findings of this paper are that N-cadherin can cause castration resistance and that therapeutic targeting of N-cadherin can delay CRPC progression. The mechanisms by which N-cadherin causes castration resistance, and by which N-cadherin-targeting antibodies inhibit it, are not known. However, N-cadherin activates gene encoding proteins previously implicated in castration resistance, such as IL-8, IL-6, TGF-β, phosphoinositide 3-kinase and AKT, and bcl-2. For example, IL-8 is sufficient to cause castration resistance in androgen-dependent LNCaP and LAPC4 cells 16 . It has been shown that introduction of IL-8 leads to a decrease or loss in androgen receptor expression 16 , similar to what we saw with N-cadherin. N-cadherin-specific antibody 2A9 may act in part by reducing IL-8 secretion. Alternatively, the decrease in IL-8 could reflect the reduction in tumor volume caused by 2A9. One possible practical application of this observation would be to use IL-8 as a surrogate marker of antibody activity in future clinical trials. AKT has also been implicated in CRPC 23 . N-cadherin upregulated AKT activity, and exposure of PC-3 and LNCaP-C1 cells to 2A9 reduced this activity, even in PTEN-null cell lines. These data suggest that inhibition of N-cadherin-regulated AKT activation might be another mechanism by which 2A9 exerts its antitumor effect.
It is not clear why antibody 2A9 is superior to antibody 1H7 in some experiments. Although both antibodies could block invasion and metastasis, only 2A9 could reliably affect the growth of larger tumors or substantially delay progression to castration resistance. One possibility is that the epitope on the fourth extracellular domain recognized by 2A9 is essential for N-cadherin signaling, particularly in castration-resistant growth 24 . Alternatively, the differential activity could be related to differences in affinity or immune activation (antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity). Additional work will be required to understand the roles of the antibodies or the epitopes they recognize.
The finding that N-cadherin-targeted antibodies delay castrationresistant progression and inhibit growth, invasion and metastasis raises the possibility that these antibodies may be translatable to the clinic. Their toxicity is one question that needs to be addressed, as N-cadherin is expressed broadly in normal tissues such as peripheral nerve, heart and liver. Loss of N-cadherin can disrupt the intercalated disc structure in the heart, leading to ventricular tachycardia and sudden death in conditional-knockout mice 25 . Because 1H7 crossreacts with mouse and human N-cadherin, we checked mice treated with 1H7 for signs of cardiac or other distress. Even at doses of 40 mg per kg body weight, we saw no evidence of toxicity, with no cases of sudden death, histologic heart abnormalities or changes in serum cardiac enzymes. These results suggest that therapeutic targeting of N-cadherin may be safe, although further preclinical and clinical testing will be required to confirm the safety of this approach. 
ONLINE METhODS
Cell culture. LNCaP-FGC, MDA-PCa-2b and PC-3 cells were from the American Type Culture Collection and cultured as specified. LNCaP-CL1 cells 14 were provided by C.L. Tso and maintained in phenol-red-free RPMI-1640 with 10% charcoal stripped serum (DCC-FBS). LAPC4 and LAPC9 xenografts were passaged in male severe combined immunodeficient (SCID) mice 26 (Taconic).
Antibodies. Western blot analysis was performed as previously described 27 with antibodies specific for N-cadherin (3B9 from Invitrogen, clone 32 from BD Transduction Laboratories), E-cadherin (Zymed Laboratories), vimentin (Thermo Scientific), androgen receptor, glyceraldehyde 3-phosphate dehydrogenase (Santa Cruz Biotechnology), AKT and phospho-AKT (Cell Signaling Technology). Immunohistochemistry was performed as previously described 28 , with antibodies specific for CD31 (Santa Cruz Biotechnology), vimentin, Ki-67 (DakoCytomation) and caspase-3 (Cell Signaling Technology). Flow cytometry was performed with N-cadherin-specific antibody GC-4 (Sigma).
Establishment of N-cadherin-overexpressing and N-cadherin-knockdown cells. Full-length N-cadherin cDNA was subcloned into the lentiviral vector CSCG (Addgene) to make CSCG-N-cadherin. The lentiviral stock was produced in 293T cells by transfecting 6.25 μg CSCG-N-cadherin, 2.5 μg envelope plasmid VSVG and 6.25 μg packaging plasmid pΔVPR (provided by I. Chen). LNCaP-FGC, MDA-PCa-2b and LAPC4 cells were transduced with either CSCG-N-cadherin or CSCG-GFP lentiviruses and sorted for positive cells. LNCaP-C1, LNCaP-C2 and LNCaP-C3 were derived through limiting dilution and screening individual clones by RT-PCR for varying levels of N-cadherin and androgen receptor expression. For stable knockdown, shRNA against N-cadherin was subcloned into the GFP-positive lentiviral vector FG-12 (Addgene) to make FG12-shNcad. Scrambled shRNA was also used to make control vector. Lentiviruses were produced as described above and used to transduce PC3 and CL1 cells. One week after transduction, FG12-shNcad-transduced cells were labeled with N-cadherin-specific antibody and sorted by flow cytometry, gating for a GFP-positive, N-cadherin low population. The cell lines with control vector were not sorted but were confirmed to be >50% GFP positive. After the sort, cells were immediately implanted in castrated mice as described below (in vivo assays).
Purification and characterization of N-cadherin-specific monoclonal antibodies. The 1H7 (IgG1-κ) and 2A9 (IgG2a-κ) N-cadherin-specific hybridomas were raised against His-tagged N-cadherin proteins representing the first three and fourth extracellular domains as previously described 26 and screened by ELISA 13 and FACS. Hybridomas were cultured in HL-1 medium (Lonza) in Integra CL 1000 flasks following the manufacturer's instructions (IBS Integra Biosciences). 1H7 and 2A9 monoclonal antibodies were purified by protein-G affinity chromatography (GE), and BIAcore 3000 (Precision Antibody Service) analysis was done with recombinant His-tagged N-cadherin as antigen.
In vitro assays. Cell proliferation was measured with the CCK-8 kit (Dojindo). For attachment assays, collected cells were pretreated with 1× PBS or 80 μg ml −1 2A9 antibody at 37 °C for 2 h, plated in fibronectin-coated 96-well plates without or with 2A9 for 15 min, and washed twice with 1× PBS. Attached cells were quantified by crystal violet staining. Invasion assays were performed in 24-well Matrigel invasion chambers (BD Biosciences) as previously described 26 , in the presence of PBS control or 80 μg ml −1 2A9 for 48 h. For knockdown experiments, cells were first transfected with commercial N-cadherin and nontargeting (control) siRNA pools, and 24 h later plated into invasion chambers, followed by quantification of invasion 48 h later. Two different pools of N-cadherin siRNA (Santa Cruz Biotechnology and Dharmacon) were used to verify the results in both cell lines.
Interleukin-8 assay. Conditioned media or mouse sera (50 μl) were assayed for IL-8 with the Human IL-8 (CXCL8) ELISA Kit (R&D Systems). Mouse blood samples were obtained retro-orbitally, and sera were separated by centrifugation.
In vivo studies. All in vivo experiments were performed according to approved protocols from the Animal Research Committee at the University of CaliforniaLos Angeles. PC3 and N-cadherin-expressing LNCaP cells (1 × 10 6 cells) in 50% Cultrex (Trevigen) were implanted subcutaneously in 6-to 8-week-old castrated male nude (Charles River) and SCID mice, respectively. LAPC9-CR xenograft tumors were collected from castrated male SCID mice and processed to single-cell suspensions as previously described 26 . We injected 1 × 10 6 cells subcutaneously into 6-to 8-week-old castrated male SCID mice. N-cadherinspecific antibody (500 μl) at 10 or 20 mg per kg body weight, or 1× PBS control was injected intraperitoneally twice weekly, when the tumors were palpable, 100 mm 3 in size or 200 mm 3 in size. Tumors were measured with calipers, and tumor volume was calculated as follows: (larger diameter) × (smaller diameter) × (third diameter, or width). To show the specificity of the N-cadherin-specific antibody, we did an initial experiment with N-cadherin-negative LAPC9-AD and N-cadherin-positive LAPC-9CR tumors, which showed antibody efficacy only in the positive tumors (data not shown).
For progression to castration-resistant studies, LAPC9-AD xenograft tumors were collected from intact male SCID mice, and 1 × 10 6 cells were injected subcutaneously into either intact or castrated 6-to 8-week-old male SCID mice pretreated with either PBS control or 10 mg kg −1 body weight N-cadherinspecific antibody. Thereafter, treatments were performed twice a week, and tumor volumes were monitored as described above.
Statistical analyses.
Data are shown as means ± s.e.m. Where indicated, P values were determined by unpaired Student's t test. P ≤ 0.05 was considered significant. 
